About Evans Capital
Evans Capital is a venture capital firm founded in 2019. It is primarily based out of Boston, United States. As of Mar 2022, Evans Capital has invested in 9 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and Consumer. Most recently it participated in the $***** Series A round of NextRNA Overall, Evans Capital portfolio has seen 2 IPOs and 2 acquisitions including key companies like Reverb, C4 Therapeutics and Frequency Therapeutics. A lot of funds co-invest with Evans Capital, with names like Carom Growth Partners sharing a substantial percentage of its portfolio. Evans Capital has team of 7 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A & Series D
Portfolio IPOs
Portfolio Acquisitions
Evans Capital's List of Top Investments
Evans Capital has a portfolio of 9 companies. Their most notable investmentis in Clockworks AnalyticsTheir portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, Consumer and 9 other sectors, across stages such as Series A, Series D stages. Here is the list of top investments by Evans Capital:1. Reverb
Online marketplace for used musical instruments. Users can sell used, vintage, and hand-made guitars and other musical instruments. Sellers can sign up and list online while buyers can browse instruments and contact sellers on the platform for bargaining and shipping details.
Key facts about Reverb
- Founded Year: 2013
- Location: Chicago (United States)
- Stage: Acquired
- Total Funding till date: $47M
- Employee Count: 250 as on Apr 30, 2026
- Investors: Lightbank, FJ Labs and 11 Others
- Latest Funding Round: Series B, Aug 15, 2017, $*****
- Highlight: Acquired
Developer of small molecule drugs for treating cancer. Its Degronimid platform incorporates highly selective small-molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural proteasome system. It has developed CFT7455 for treating hematologic malignancies, CFT8634 for sarcoma, BRAF V600E for slid tumors.
Key facts about C4 Therapeutics
- Founded Year: 2016
- Location: Cambridge (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $223M
- Employee Count: 110 as on Apr 30, 2026
- Investors: HTIF, Bain Capital Life Sciences and 27 Others
- Latest Funding Round: Post IPO, Jan 04, 2024, $*****
- Highlight: Public
Developing regenerative therapeutic for reversing hearing loss. The company's lead candidate FX-322 for sensorineural hearing loss and remyelination in multiple sclerosis. These small-molecule therapeutics selectively activate progenitor cells already present in the body that helps to create healthy functional tissues and organs.
Key facts about Frequency Therapeutics
- Founded Year: 2015
- Location: Cambridge (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $136M
- Employee Count: 48 as on Feb 28, 2023
- Investors: RTW Investments, Deerfield and 21 Others
- Latest Funding Round: Post IPO, Jul 22, 2020, $*****
- Highlight: Public
128 Technology is a cloud-based networking platform for distributed routing and network services provider. Features include delivery of applications and services across multiple networks, virtual networking overlay, zero-trust network security, and consolidation of stand-alone network services. Use cases include next-generation WAN, data center interconnect, and network-as-a-service. Clients include CMC Networks, Revation, and RedVine.
Key facts about 128 Technology
- Founded Year: 2014
- Location: Burlington (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $113M
- Employee Count: 49 as on Apr 30, 2026
- Investors: The Perkins Fund, Broadway Angels and 3 Others
- Latest Funding Round: Series D, Jul 24, 2020, $*****
- Highlight: Acquired
Developer of building analytics software for energy performance and maintenance. The software analyzes building systems data to identify performance issues and provide diagnostic information. It offers tools for monitoring energy performance, indoor environmental quality, and equipment operation. The software helps users identify impactful issues, determine root causes, and recommend actions. It also provides task and team management features.
Key facts about Clockworks Analytics
- Founded Year: 2007
- Location: Somerville (United States)
- Stage: Series E
- Total Funding till date: $35M
- Employee Count: 112 as on Apr 30, 2026
- Investors: Schneider Electric, Aster and 4 Others
- Latest Funding Round: Series E, Aug 22, 2023, $*****
- Highlight: Editors' Pick
Evans Capital's Year-on-Year Investment Trends
Evans Capital has invested in 9 companies over the last 6 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in NextRNA.Evans Capital's Investments by Stage
Evans Capital has made 1 investment in Series A stage with an average round size of $46.8M and 1 investment in Series D stage with an average round size of $8M.Evans Capital's Investments by Sector
Evans Capital has a diverse portfolio, with companies operating in the Energy Tech, Enterprise Applications, Environment Tech, Healthcare and Life Sciences. Notably, it has invested in 8 Enterprise (B2B) companies, 8 Tech companies, 2 Saas companies and at least 2 companies focusing on Software.Sector | No. of Investments |
|---|---|
Energy Tech | 1 |
Enterprise Applications | 1 |
Environment Tech | 1 |
Healthcare | 1 |
Life Sciences | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Evans Capital's Investments by Geography
Evans Capital has made most investments in United States (2).Evans Capital's recent investments
Evans Capital has not made any investment in 2026 so far.Here are the most recent investments by Evans Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 01, 2022 | United States | Series A | 4010 | [+5] | |
Dec 09, 2020 | United States | Series D | 2707 |
IPOs and Publicly Listed companies in Evans Capital's Portfolio
2 of Evans Capital's portfolio companies have become public. C4 Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2020 at marketcap of $789M and Frequency Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $426M.Here are Evans Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 02, 2020 | - | - | 7612 | |
Oct 03, 2019 | - | - | 4797 |
Acquired companies in Evans Capital's Portfolio
2 companies from Evans Capital's portfolio have been acquired. The most recent acquisition was Reverb in Apr 2025 by Creator Partners for $*****.Here are Evans Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 29, 2025 | - | - | 1258 | |
Oct 19, 2020 | - | - | 3907 |
Team profile of Evans Capital
Evans Capital has a team of 7 members including 4 Partners and 1 Principal located in United States. Evans Capital's team sits on the board of 1 company.Here is a list of all team members in Evans Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Boston | |||
Partner | - | - | - | |
Partner | Santa Rosa | - | - | |
Partner | Reynoldsburg | - | - | |
Principal | Boston | - | - |
Co-investors of Evans Capital
Over the past 6 years, 10 investors have co-invested in Evans Capital's portfolio companies. This includes funds and angels.
- Invested before Evans Capital: Schneider Electric and Riverside have invested in rounds before Evans Capital. There is 1 company where Schneider Electric has invested before Evans Capital and 1 company where Riverside has invested before Evans Capital.
- Top Co-investors of Evans Capital: 8 investors entered a company along with Evans Capital. These include investors like Carom Growth Partners (1 company).
Recent News related to Evans Capital
•
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to PatientsBusiness Wire•Mar 01, 2022•NextRNA, Cobro Ventures, Lightchain Capital, Circle Squared and 4 others
